Reducing Safety-Related Drug Attrition- An Interview with Gareth Waldron

Gerald Clarke

Safety-related drug attrition is obviously a huge problem in drug trials. How can companies work to reduce this? We spoke with Gareth Waldron Non-Clinical Safety Lead at Pfizer Neusentis about in vitro pharmacological profiling, how it could be implemented to reduce this attrition and the success stories so far. [inlinead]
To continue reading this story get free access